Irinomedac

Irinotecan, the active ingredient in Irinomedac, is a topoisomerase I inhibitor presented as an injection solution for intravenous use. It treats metastatic colorectal cancer, is used as adjuvant therapy for colon cancer, and has off‑label application in small cell lung cancer.

GNH USA supplies Irinomedac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is employed in oncology regimens targeting specific solid tumours.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy. Adjuvant treatment of colon cancer: reduces the risk of disease recurrence after surgical resection. Small cell lung cancer (off‑label): may be incorporated into combination chemotherapy protocols for disease control.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness during treatment. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or intestinal perforation. - Hepatotoxicity: elevated liver enzymes or liver dysfunction. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Hand‑foot syndrome: painful redness and swelling of palms and soles. - Cardiotoxicity: rare cardiac rhythm disturbances.

Prior to initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

Monitor blood counts: perform regular complete blood counts to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during treatment. Screen for bowel obstruction: consider baseline imaging in patients with prior abdominal surgery. Adjust dose in hepatic impairment: reduce dosage according to liver function test results. Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): decrease irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase SN‑38 levels and toxicity. - Concurrent myelosuppressive agents: amplify risk of severe neutropenia. - Anticholinergic drugs: may exacerbate irinotecan‑induced diarrhea. - Live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): raise irinotecan plasma concentrations. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - Proton pump inhibitors: possible alteration of gastric pH affecting absorption of oral metabolites. - Herbal supplements (e.g., St. John’s wort): may induce metabolic enzymes.